DOW JONES21,052.53-360.91 -1.69%
S&P 5002,488.65-38.25 -1.51%
NASDAQ7,373.08-114.23 -1.53%

Baird Upgrades Enanta Pharmaceuticals to Outperform, Announces $60 Price Target

Baird analyst Brian Skorney upgrades Enanta Pharmaceuticals (NASDAQ:ENTA) from Neutral to Outperform and announces $60 price target.

Benzinga · 03/17/2020 11:30

Baird analyst Brian Skorney upgrades Enanta Pharmaceuticals (NASDAQ:ENTA) from Neutral to Outperform and announces $60 price target.